Cemile PEHLİVANOĞLU, Ilmay BİLGE, Bağdagül AKSU, Alev YILMAZ, Zeynep YÜRÜK YILDIRIM, Yasin YILMAZ, Işın KILIÇASLAN, Sevinç EMRE

Yaşamı Tehdit Eden Sistemik Lupus Eritematozus Vakasında Rituksimab Tedavisi

Sistemik Lupus Eritematozus, heterojen otoinflamatuar bir hastalıktır. Patofizyolojisinde genetik nedenlerin yanında çevresel multifaktöryel etkenler suçlanmıştır. B hücrelerinin aşırı aktivasyonunun lupus patofizyolojisin- de önemli rol oynadığı gösterilmiştir. Çocuklarda tedavi- sinde steroidler ve immunsupresif ajanlar kullanılmakta- dır. Rituksimab, B lenfositlerin CD20 antijenlerine karşı geliştirilen bir biyolojik ajandır. B hücrelerine bağlı oto- inflamatuvar hastalıklarda etkin olduğu gösterilmiştir. Bu makalede, ciddi komplikasyonları olan ve diğer immun- supresif tedavilere yanıt vermeyen sistemik lupus eritema- tozus tanılı çocuk vakasında rituksimab tedavisi deneyimi paylaşılacaktır

Anahtar Kelimeler:

Sistemik Lupus Eritematozus, rituksimab, immunsupresif ajanlar

Rituximab Treatment of A Case with Life-Threatening Systemic Lupus Erythematosus

Systemic Lupus Erythematosus SLE is a heterogeneous autoinflammatory disease. Genetic and environmental multi- factorial agents have been implicated in its pathophysiology. Hyperactivation of B cells has been demonstrated to play a central role in SLE pathophysiology. Steroids and immuno- suppressive agents are administered in the treatment of child- ren. Rituximab is a biologic agent developed against CD20 antigens of B cells. It has been shown that rituximab is effec- tive in B cell-dependent autoinflammatory diseases. In this paper, we will share our experience about rituximab treatment of a pediatric case with the diagnosis of lupus erythematosus with severe complications and unresponsive to other immuno- suppressive therapies

Keywords:

Systemic Lupus Erythematosus SLE, rituximab, immunosuppressive agents,

PDF

___

mir S, keskinoğlu a. Çocukluk çağı lupus nefriti izle- minde anti-dsDNA düzeyi. Ege Tıp Dergisi 2003;42(1):19-24.
makay B, ünsal E. Jüvenil sistemik lupus eritemato- zus. Klinik Gelişim 2006;19(1):24-33.
Livingston B, Bonner a, Pope J. Differences in clini- cal manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis. Lupus 2011;20(13): 1345-55. http://dx.doi.org/10.1177/0961203311416694
Vachvanichsanong P, mcneil E. Pediatric lupus neph- ritis: more options, more chances? Lupus 2013;22(6): 545-53. http://dx.doi.org/10.1177/0961203313485490
rovin Bh, Furie r, Latinis k, Looney rJ, Fervenza FC, Sanchez-Guerrero J et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum 2012;64(4):1215-26. http://dx.doi.org/10.1002/art.34359
Pinto LF, Velásquez CJ, Prieto C, mestra L, Forero E, márquez Jd. Rituximab induces a rapid and susta- ined remission in Colombian patients with severe and refractory systemic lupus erythematosus. Lupus 2011;20(11):1219-26. http://dx.doi.org/10.1177/0961203311409273
davies rJ, Sangle Sr, Jordan nP, aslam L, Lewis mJ, Wedgwood r et al. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. Lupus 2013; 22(6):574-82. http://dx.doi.org/10.1177/0961203313483376
Trachana m, koutsonikoli a, Farmaki E, Printza n, Tzimouli V, Papachristou F. Safety and efficacy of rituximab in refractory pediatric systemic lupus erythe- matosus nephritis: a single-center experience of Northern Greece. Rheumatol Int 2013;33(3):809-13. http://dx.doi.org/10.1007/s00296-011-2239-6
Willems m, haddad E, niaudet P, koné-Paut I, Bensman a, Cochat P et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 2006;148(5):623-27. http://dx.doi.org/10.1016/j.jpeds.2006.01.041
Lehman TJ, Singh C, ramanathan a, alperin r, adams a, Barinstein L et al. Prolonged improvement of childhood onset systemic lupus erythematosus follo- wing systematic administration of rituximab and cyclophosphamide. Pediatr Rheumatol Online J 2014; 12:3. http://dx.doi.org/10.1186/1546-0096-12-3